Skip to main content

7 Result(s)

within A. G. Harris Remove this filter Endocrinology Remove this filter

and

  1. Article

    Open Access

    Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial

    In a phase 2 trial of 222 postmenopausal women with osteoporosis aged 55 to 85 years randomized to one of three different doses of abaloparatide-SC, subcutaneous teriparatide, or placebo for 24 weeks, abalopar...

    J. P. Bilezikian, G. Hattersley, L. A. Fitzpatrick… in Osteoporosis International (2018)

    Download PDF (431 KB) View Article

  2. No Access

    Article

    A prospective multicenter octreotide dose response study in the treatment of acromegaly

    The somatostatin analog octreotide has proven to be an effective form of treatment for various hypersecretory states including acromegaly. This report describes the effects of escalating doses of octreotide on...

    Shereen Ezzat M.D., D. A. Redelmeier, M. Gnehm… in Journal of Endocrinological Investigation (1995)

  3. No Access

    Chapter and Conference Paper

    Heart Size Reduction in Acromegalic Patientes Treated with the Long-Acting Somatostatin-Analogue SMS 201–995 (Somatostatin®)

    Cardiomegaly by hypertrophy of the heart in acromegalic patients — prevalence 85% in our patients with acromegaly [1] — is often complicated by complex arrhythmias and gradual cardiac-insufficiency [1, 3, 8]. ...

    P.-H. Althoff, K. Schmidt, D. Rübesam, A. G. Harris… in Endocrinology of the Heart (1989)

  4. No Access

    Chapter and Conference Paper

    Effects of Long-Term Administration of Sandostatin® (SMS 201–995) at Increasing Doses in 40 Acromegalic Patients. Results from the French Sandostatin Acromegaly Study Group

    Several studies demonstrate the efficacy of short- and long-term Sandostatin® treatment in acromegaly administered subcutaneously at doses ranging from 150 to 300 µg up to 600 µg per day [1, 3, 5, 7–10]. A rhythm...

    G. Sassolas, P. Fossati, P. Chanson… in Sandostatin® in the Treatment of Acromegaly (1988)

  5. No Access

    Chapter and Conference Paper

    Observations During a Clinical Trial of Sandostatin® in Acromegalic Patients

    Ten acromegalic patients were studied over a period of 75 weeks. Four had had one or more attempted ablations of their pituitary adenoma, six were previously untreated or had been unsuccessfully treated with b...

    H. Ørskov, J. Weeke, S. E. Christensen… in Sandostatin® in the Treatment of Acromegaly (1988)

  6. No Access

    Chapter and Conference Paper

    Long-Term Treatment of Acromegaly by Continuous Subcutaneous Infusion of the Long-Acting Somatostatin Analog Sandostatin® (SMS 201–995, Octreotide)

    Recently the long-acting somatostatin analog Sandostatin® (SMS 201–995, Octreotide) was introduced for the therapy of acromegaly. On a two or three daily subcutaneous (s.c.) injection regimen plasma GH levels hav...

    J. P. Tauber, Th. Babin, M. C. R. Ducasse… in Sandostatin® in the Treatment of Acromegaly (1988)

  7. No Access

    Chapter and Conference Paper

    Long-Term Efficacy of Sandostatin®(SMS 201–995, Octreotide) in 178 Acromegalic Patients. Results from the International Multicentre Acromegaly Study Group

    Sandostatin® (SMS 201–995), a synthetic long-acting octapeptide, represents an efficacious alternative therapeutic candidate to available treatment modalities for acromegaly.

    A. G. Harris, H. Prestele, K. Herold… in Sandostatin® in the Treatment of Acromegaly (1988)